Profile | GDS2987 / GI_5031954-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 17.4 | 51 |
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | 19.2 | 45 |
GSM215282 | HMVEC_atorvastatin_rep3 | 42.8 | 65 |
GSM215344 | HMVEC_atorvastatin_rep2 | 3.2 | 8 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 22.1 | 40 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 39.8 | 54 |
GSM215294 | HMVEC_SLx2119_rep1 | 15.9 | 49 |
GSM215295 | HMVEC_SLx2119_rep2 | 2.1 | 4 |
GSM215296 | HMVEC_SLx2119_rep3 | 17.1 | 28 |
GSM215297 | PASMC_vehicle_rep1 | 48.1 | 57 |
GSM215298 | PASMC_vehicle_rep2 | 31.1 | 44 |
GSM215310 | PASMC_vehicle_rep3 | 21.8 | 34 |
GSM215311 | PASMC_atorvastatin_rep1 | 32.5 | 49 |
GSM215312 | PASMC_atorvastatin_rep2 | 37.2 | 50 |
GSM215313 | PASMC_atorvastatin_rep3 | 32.7 | 44 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 41.8 | 56 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 31.5 | 51 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 24.6 | 41 |
GSM215329 | PASMC_SLx2119_rep3 | 12 | 23 |
GSM215330 | Fibroblasts_vehicle_rep1 | 0.5 | 1 |
GSM215331 | Fibroblasts_vehicle_rep2 | 16.8 | 43 |
GSM215332 | Fibroblasts_vehicle_rep3 | 13.1 | 40 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 20.9 | 48 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 15.5 | 40 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 3.3 | 11 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 19.5 | 51 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 47.5 | 68 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 23.5 | 54 |
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 | 15.5 | 37 |